ReviewCalcified tissue international2018
Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus.
Review in Calcified tissue international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Global prevalence, site-specific patterns, and key risk factors for osteoporosis and bone loss in systemic lupus erythematosus: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Blockade of NLRP3 alleviates systemic lupus erythematosus-induced osteoporosis through dual modulation of osteogenesis and osteoclastogenesis.Bone reports · 2026Article
- Outcomes Following Single-Level Spinal Fusion in Patients With Systemic Lupus Erythematosus.Cureus · 2026Article
- Fertility, pregnancy and lactation in women with systemic lupus erythematosus.Nature reviews. Rheumatology · 2026Review
- Risk factor of osteoporosis in systemic lupus erythematosus patients: a cross-sectional study in a tertiary hospital in Indonesia.Lupus science & medicine · 2026Article
- Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Prevalence and determinants of vertebral fractures in a SLE cohort.Lupus science & medicine · 2025Observational
- Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.Lupus science & medicine · 2025Article
- Ten tips in lupus nephritis management.Clinical kidney journal · 2025Review
- Factors affecting bone mineral density in children and adolescents with systemic lupus erythematosus.Annals of pediatric endocrinology & metabolism · 2024Article
- Combined application of mesenchymal stem cells and different glucocorticoid dosing alleviates osteoporosis in SLE murine models.Immunity, inflammation and disease · 2024Article
- Association between systemic lupus erythematosus and osteoporosis: a mendelian randomization analysis.BMC rheumatology · 2024Article
- The Relationship Between Systemic Lupus Erythematosus and Osteoporosis Based on Different Ethnic Groups: a Two-Sample Mendelian Randomization Analysis.Calcified tissue international · 2024Article
- Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.Journal of clinical medicine · 2024Review
- Lipopolysaccharide Impedes Bone Repair inInternational journal of molecular sciences · 2023Article
- Immunoglobulin G inhibits glucocorticoid-induced osteoporosis through occupation of FcγRI.iScience · 2023Article
- Long-Term Use of Immunosuppressive Agents Increased the Risk of Fractures in Patients with Autoimmune Diseases: An 18-Year Population-Based Cohort Study.Biomedicines · 2023Article
- Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density.Lupus science & medicine · 2023Article
- Racial differences in persistent glucocorticoid use patterns among medicaid beneficiaries with incident systemic lupus erythematosus.Seminars in arthritis and rheumatism · 2023Article
- The applications of functional materials-based nano-formulations in the prevention, diagnosis and treatment of chronic inflammation-related diseases.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews recent advances in the research of the mechanisms of bone loss, as well as clinical features, economic impact and therapeutic implications of osteoporosis and fractures in patients with systemic lupus erythematosus (SLE) as an illustration of bone disease in a complex systemic autoimmune connective tissue disease. Recent studies demonstrated an increased incidence of osteoporosis and peripheral and vertebral fractures in patients with SLE. The aetiology of bone loss in SLE is multifactorial, including clinical osteoporosis risk factors, systemic inflammation, serological factors, metabolic factors, hormonal factors, possibly genetic factors and medication-induced adverse effects. The incidence of symptomatic fractures in patients with SLE is increased 1.2-4.7-fold and age, disease duration, glucocorticoid use, previous cyclophosphamide use, seizures and a prior cerebrovascular event have been identified as important risk factors. Moreover, a high prevalence of morphometric vertebral fractures was demonstrated, while one in three of these patients has normal bone density, which finding points to the multifactorial aetiology of fractures in SLE. The clinical consequences and economic burden of osteoporosis and fractures as glucocorticoid treatment-related adverse events and the high frequency of glucocorticoid therapy underline the importance of reducing glucocorticoid treatment and prescribing steroid-sparing agents. No data on fall risk and its determinants and the relationship with the occurrence of fractures in patients with SLE are currently available. Fall risk might be increased in lupus patients for several reasons. In addition, the recently reported high prevalence (20%) of frailty in SLE patients may contribute to the increased fracture incidence. Therefore, the relationships between fall risk, frailty and fracture occurrence in SLE might be interesting subjects for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.